SAN DIEGO, July 15 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. will Webcast its Quarterly Update Conference Call for the second quarter of 2008 on Monday, July 21, 2008 at 5:00 p.m. ET/2:00 p.m. PT. Daniel M. Bradbury, Amylin’s President and Chief Executive Officer, will lead the call. On the same date post-market, Amylin will release financial results for the second quarter of 2008.
The call will be Webcast live through Amylin’s corporate Web site and a recording will be made available following the close of the call. To access the Webcast, please log on to http://www.amylin.com approximately fifteen minutes prior to the call to register, download and install any necessary audio software. For those without access to the Internet, the live call may be accessed by phone by calling (866) 244-4530 (U.S./Canada) or (703) 639-1173 (international), Conference ID# 1262019. A replay of the call will also be available by phone beginning approximately two hours after the close of the call and can be accessed at (888) 266-2081 (U.S./Canada) or (703) 925-2533 (international), Conference ID# 1262019.
About Amylin Pharmaceuticals, Inc.
Amylin Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin’s research and development activities leverage the company’s expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is located in San Diego, California with over 2,000 employees nationwide. Further information on Amylin Pharmaceuticals is available at http://www.amylin.com.
CONTACT: Michael York, Senior Director, Investor Relations of Amylin
Pharmaceuticals, Inc., +1-858-552-2200, ext. 8602
Web site: http://www.amylin.com/
